Article: SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleSARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
AuthorsWoo, PCY1 4
Lau, SKP1 4
Tsoi, HW1
Chen, ZW2
Wong, BHL1
Zhang, L2
Chan, JKH1
Wong, LP1
He, W3
Ma, C3
Chan, KH1 4
Ho, DD2
Yuen, KY1 4
Issue Date2005
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
CitationVaccine, 2005, v. 23 n. 42, p. 4959-4968 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2005.05.023
AbstractDifferent forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of ≥1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems. © 2005 Elsevier Ltd. All rights reserved.
ISSN0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
DOIhttp://dx.doi.org/10.1016/j.vaccine.2005.05.023
ISI Accession Number IDWOS:000232265200001
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorWoo, PCY
dc.contributor.authorLau, SKP
dc.contributor.authorTsoi, HW
dc.contributor.authorChen, ZW
dc.contributor.authorWong, BHL
dc.contributor.authorZhang, L
dc.contributor.authorChan, JKH
dc.contributor.authorWong, LP
dc.contributor.authorHe, W
dc.contributor.authorMa, C
dc.contributor.authorChan, KH
dc.contributor.authorHo, DD
dc.contributor.authorYuen, KY
dc.date.accessioned2010-09-06T07:53:06Z
dc.date.available2010-09-06T07:53:06Z
dc.date.issued2005
dc.description.abstractDifferent forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of neutralizing antibody response against SARS-CoV were compared using a mouse model. High IgG levels were detected in mice immunized with intraperitoneal (i.p.) recombinant spike polypeptide generated by Escherichia coli (S-peptide), mice primed with intramuscular (i.m.) tPA-optimize800 DNA vaccine (tPA-S-DNA) and boosted with i.p. S-peptide, mice primed with i.m. CTLA4HingeSARS800 DNA vaccine (CTLA4-S-DNA) and boosted with i.p. S-peptide, mice primed with oral live-attenuated Salmonella typhimurium (Salmonella-S-DNA-control) and boosted with i.p. S-peptide, mice primed with oral live-attenuated S. typhimurium that contained tPA-optimize800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide, and mice primed with oral live-attenuated S. typhimurium that contained CTLA4HingeSARS800 DNA vaccine (Salmonella-tPA-S-DNA) and boosted with i.p. S-peptide. No statistical significant difference was observed among the Th1/Th2 index among these six groups of mice with high IgG levels. Sera of all six mice immunized with i.p. S-peptide, i.m. DNA vaccine control and oral Salmonella-S-DNA-control showed no neutralizing antibody against SARS-CoV. Sera of the mice immunized with i.m. tPA-S-DNA, i.m. CTLA4-S-DNA, oral Salmonella-S-DNA-control boosted with i.p. S-peptide, oral Salmonella-tPA-S-DNA, oral Salmonella-tPA-S-DNA boosted with i.p S-peptide, oral Salmonella-CTLA4-S-DNA and oral Salmonella-CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of <1:20-1:160. Sera of all the mice immunized with i.m. tPA-S-DNA boosted with i.p. S-peptide and i.m. CTLA4-S-DNA boosted with i.p. S-peptide showed neutralizing antibody titers of ≥1:1280. The present observation may have major practical value, such as immunization of civet cats, since production of recombinant proteins from E. coli is far less expensive than production of recombinant proteins using eukaryotic systems. © 2005 Elsevier Ltd. All rights reserved.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationVaccine, 2005, v. 23 n. 42, p. 4959-4968 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2005.05.023
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2005.05.023
dc.identifier.epage4968
dc.identifier.hkuros114672
dc.identifier.isiWOS:000232265200001
dc.identifier.issn0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
dc.identifier.issue42
dc.identifier.openurl
dc.identifier.pmid15993989
dc.identifier.scopuseid_2-s2.0-24644485207
dc.identifier.spage4959
dc.identifier.urihttp://hdl.handle.net/10722/79306
dc.identifier.volume23
dc.languageeng
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVaccine
dc.relation.referencesReferences in Scopus
dc.rightsVaccine. Copyright © Elsevier Ltd.
dc.subject.meshAdministration, Oral
dc.subject.meshAnimals
dc.subject.meshAntibodies, Viral - blood - immunology
dc.subject.meshBacterial Vaccines - administration & dosage - immunology
dc.subject.meshEscherichia coli Proteins
dc.subject.meshImmunization Schedule
dc.subject.meshImmunization, Secondary
dc.subject.meshImmunoglobulin G - blood
dc.subject.meshInjections, Intramuscular
dc.subject.meshInjections, Intraperitoneal
dc.subject.meshInterferon-gamma - analysis
dc.subject.meshInterleukin-4 - analysis
dc.subject.meshMale
dc.subject.meshMembrane Glycoproteins - administration & dosage - genetics - immunology
dc.subject.meshMice
dc.subject.meshMice, Inbred BALB C
dc.subject.meshModels, Animal
dc.subject.meshNeutralization Tests
dc.subject.meshSARS Virus - immunology
dc.subject.meshSevere Acute Respiratory Syndrome - prevention & control
dc.subject.meshVaccines, DNA - administration & dosage - immunology
dc.subject.meshVaccines, Synthetic - administration & dosage - immunology
dc.subject.meshViral Envelope Proteins - administration & dosage - genetics - immunology
dc.titleSARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong
  2. Aaron Diamond AIDS Research Center
  3. Peking Union Medical College
  4. Faculty of Medicine